The development of hepatocellular carcinoma (HCC) is closely related to the formation of tumour blood vessels. VEGF-mediated angiogenesis is a major driver of the immune escape response in tumours. VEGF binds to vascular endothelial growth factor receptor2 (VEGFR2) on endothelial cells, promoting endothelial cell proliferation and migration, inducing vascular changes in HCC, and thus promote the growth of hepatocellular carcinoma cells. Anti-VEGF and its receptor-targeted molecular drugs are currently effective new treatments for HCC. Monoclonal antibodies against VEGF and small-molecule tyrosine kinase inhibitors targeting VEGF have been shown to block its angiogenic activity, alleviate the inhibitory effect of the tumour microenvironment, and ultimately achieve tumour regression. This article provides a review of the research progress of VEGF/VEGFR inhibitors in HCC treatment.